Thomas Först

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

John B. Buse, Michael A. Nauck, Thomas Först et al. · The Lancet · 2012 · 559 citations

Diabetes Management, Diabetes, Type 2 +5

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

Kathleen Dungan, Santiago Tofé, Thomas Först et al. · The Lancet · 2014 · 477 citations

Diabetes Management, Once-weekly Dulaglutide, Diabetes +6

Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control

Andreas Pfützner, Nikolaus Marx, G Lübben et al. · Journal of the American College of Cardiology · 2005 · 270 citations

Metabolic Syndrome, Cardiovascular Disease, Pioglitazone Is Independent +8